Drugs / bcr/abl breakpoint peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00004052 | Mar 1999 → Aug 2005 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bcr/abl breakpoint peptide vaccine | “Patients receive bcr/abl breakpoint peptide vaccine in QS21 adjuvant subcutaneously” NCT00004052 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill cancer cells.” NCT00004052 ↗ |
| Modality | Vaccine | “multivalent tumor-specific breakpoint peptide vaccine” NCT00004052 ↗ |
| Route | Subcutaneous | “bcr/abl breakpoint peptide vaccine in QS21 adjuvant subcutaneously” NCT00004052 ↗ |